ACA
IBB icon

Aptus Capital Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Aptus Capital Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$367K Hold
1,929
– – ﹤0.01% 878
2026
Q1 		$326K Sell
1,929
-202,433
-99% -$34.6M ﹤0.01% 847
2025
Q4 		$34.5M Buy
204,362
+202,269
+9,664% +$32.9M 0.25% 76
2025
Q3 		$302K Sell
2,093
-175
-8% -$23.9K ﹤0.01% 842
2025
Q2 		$287K Sell
2,268
-688
-23% -$84.5K ﹤0.01% 837
2025
Q1 		$378K Buy
2,956
+920
+45% +$125K ﹤0.01% 721
2024
Q4 		$269K Buy
2,036
+1,610
+378% +$226K ﹤0.01% 803
2024
Q3 		$62K Buy
426
+114
+37% +$16.5K ﹤0.01% 903
2024
Q2 		$42.8K Sell
312
-25
-7% -$3.34K ﹤0.01% 909
2024
Q1 		$46.2K Sell
337
-402
-54% -$54.9K ﹤0.01% 900
2023
Q4 		$100K Sell
739
-5,330
-88% -$650K ﹤0.01% 616
2023
Q3 		$742K Buy
6,069
+4,094
+207% +$521K 0.02% 330
2023
Q2 		$251K Buy
1,975
+93
+5% +$12.1K 0.01% 445
2023
Q1 		$243K Sell
1,882
-36
-2% -$4.71K 0.01% 431
2022
Q4 		$252K Sell
1,918
-1,267
-40% -$164K 0.01% 434
2022
Q3 		$373K Buy
3,185
+2,824
+782% +$351K 0.01% 357
2022
Q2 		$42K Hold
361
– – ﹤0.01% 483
2022
Q1 		$47K Hold
361
– – ﹤0.01% 514
2021
Q4 		$55K Hold
361
– – ﹤0.01% 423
2021
Q3 		$58K Sell
361
-35
-9% -$5.89K ﹤0.01% 402
2021
Q2 		$65K Hold
396
– – ﹤0.01% 417
2021
Q1 		$60K Hold
396
– – ﹤0.01% 393
2020
Q4 		$59K Hold
396
– – ﹤0.01% 355
2020
Q3 		$53K Sell
396
-382
-49% -$51.8K ﹤0.01% 350
2020
Q2 		$106K Buy
778
+382
+96% +$48.7K 0.01% 288
2020
Q1 		$42K Hold
396
– – ﹤0.01% 319
2019
Q4 		$47K Buy
396
+361
+1,031% +$40.3K ﹤0.01% 398
2019
Q3 		$3K Buy
+35
New +$3.66K ﹤0.01% 459

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Aptus Capital Advisors's IBB Position: Q2 2026 in Review

Aptus Capital Advisors held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 1,929 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #878.

Aptus Capital Advisors first reported a position in IBB in Q3 2019 and has held it in 28 quarters since. The position peaked at $34.5M in Q4 2025. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Aptus Capital Advisors held 1,929 shares of iShares Biotechnology ETF worth $367K as of Q2 2026.
  • Aptus Capital Advisors left its iShares Biotechnology ETF share count unchanged in Q2 2026.
  • iShares Biotechnology ETF made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #878 holding.
  • Aptus Capital Advisors first reported a position in iShares Biotechnology ETF in Q3 2019 and has held it in 28 quarters since.
  • Aptus Capital Advisors's iShares Biotechnology ETF position peaked at $34.5M in Q4 2025.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.